Evercore ISI Group Maintains Outperform on Snap, Lowers Price Target to $26
Evercore ISI Group analyst Mark Mahaney maintains Snap (NYSE:SNAP) with a Outperform and lowers the price target from $36 to $26.
Evercore ISI Group Maintains Outperform on Roku, Lowers Price Target to $140
Evercore ISI Group analyst Shweta Khajuria maintains Roku (NASDAQ:ROKU) with a Outperform and lowers the price target from $185 to $140.
Watching Toronto-Dominion Bank; The Bear Cave Issues Short Report Titled ‘Problems at Toronto-Dominion Bank (TD)’
https://thebearcave.substack.com/p/problems-at-toronto-dominion-bank
Evercore ISI Group Maintains In-Line on Netflix, Lowers Price Target to $245
Evercore ISI Group analyst Mark Mahaney maintains Netflix (NASDAQ:NFLX) with a In-Line and lowers the price target from $300 to $245.
Evercore ISI Group Maintains Outperform on Match Group, Lowers Price Target to $95
Evercore ISI Group analyst Mark Mahaney maintains Match Group (NASDAQ:MTCH) with a Outperform and lowers the price target from $115 to $95.
Evercore ISI Group Maintains Outperform on Meta Platforms, Lowers Price Target to $280
Evercore ISI Group analyst Mark Mahaney maintains Meta Platforms (NASDAQ:META) with a Outperform and lowers the price target from $325 to $280.
Evercore ISI Group Maintains Outperform on Lyft, Lowers Price Target to $42
Evercore ISI Group analyst Mark Mahaney maintains Lyft (NASDAQ:LYFT) with a Outperform and lowers the price target from $45 to $42.
Evercore ISI Group Maintains Outperform on Grab Hldgs, Lowers Price Target to $5
Evercore ISI Group analyst Mark Mahaney maintains Grab Hldgs (NASDAQ:GRAB) with a Outperform and lowers the price target from $6 to $5.
Galmed’s Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced results showing significant effects of Aramchol in a preclinical lung and gastrointestinal (GI) fibrosis model. Treatment…